Irbesartan/Amlodipine Besylate

厄贝沙坦/苯磺酸氨氯地平

Report date: 2026/03/04 20:01:44

Base Information

Drug NameIrbesartan/Amlodipine Besylate
Drug Alias NameAmlodipine besylate/Irbesartan苯磺酸氨氯地平/厄贝沙坦Irbesartan/amlodipine besilateIrbesartan - amlodipine besilate mixtAimix +[6] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsEssential HypertensionHypertension
Approved Indications in ChinaEssential Hypertension
Original Approved Country/TerritoryJapan
Original Approved Date2012/09/28
Country/TerritoryTunisiaVenezuelaMexico +[15] 
CombinationsYes IrbesartanAmlodipine Besylate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofiSumitomo Dainippon
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo DainipponHandok Inc
Inactive CompaniesHunan Huize Biomedical Technology Co LtdSanofi
Active IndicationsEssential HypertensionHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09DB05
Related LinksKEGG